Bookmark

Add to MyYahoo RSS

Bristol Myers Squibb News

News on Bristol Myers Squibb (Ticker: BMY) continually updated from thousands of sources around the net.

Yesterday | AmericanBankingNews.com

Bristol-Myers Squibb Given Consensus Recommendation of "Hold" by Analysts

Shares of Bristol-Myers Squibb have earned a consensus rating of "Hold" from the eighteen analysts that are presently covering the stock, AnalystRatings.Net reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Media, Publishing, Medarex

Sat Aug 30, 2014

Freshnews

Secondary Analysis of AMPLIFY-EXT Examining Predictors of...

Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Pa PRINCETON, N.J. & NEW YORK -- -- Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified secondary analysis of the Eliquis Phase ... (more)

Comment?

Related Topix: Princeton, NJ, Biotech, Medicine, Healthcare Industry, Pfizer, Excaliard Pharmaceuticals, Bloomsbury Publishing, Publishing, Media, Medarex

Fri Aug 29, 2014

Reuters

Germany's Bayer to launch three new Xarelto trials

Germany's Bayer said it plans to launch three new studies to add more uses for its anti-clotting drug Xarelto, one of its top five new medicines.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Johnson and Johnson

GuruFocus.com

Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model

In this article, letA s consider Bristol-Myers Squibb Company , an $83.79 billion market cap that has a trailing P/E ratio that indicates the stock is relatively undervalued .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Thu Aug 28, 2014

Medical News

Colorectal cancer therapies market to remain constant at $7.7 billion by 2023

Decision Resources Group finds that the market for colorectal cancer therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Health

Insider Monkey

Intercept Pharmaceuticals Inc. (ICPT), Bristol-Myers Squibb Co (BMY), ...

Orbimed Advisors , led by Samuel Isaly , recently published its 13F filing with the U.S. Securities and Exchange Commission.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Intercept Pharmaceuticals, US Securities and Exchange Commission, Financial Services, Venture Capital, Emerging Technology, Biogen Idec

Wed Aug 27, 2014

AmericanBankingNews.com

Bristol-Myers Squibb Research Coverage Started at Deutsche Bank

In other Bristol-Myers Squibb news, SVP Autenried Paul Von sold 20,000 shares of the stock on the open market in a transaction dated Tuesday, August 19th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bristol Myers Squibb, Bristol-Myers Squibb, Bloomsbury Publishing, Media, Publishing, Medarex, Pharmaceuticals

TheStreet.com

Will This Coverage Initiation Affect Bristol-Myers Squibb (BMY) Stock Today?

Separately, TheStreet Ratings team rates BRISTOL-MYERS SQUIBB CO as a "buy" with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation: "We rate BRISTOL-MYERS SQUIBB CO a BUY.

Comment?

Related Topix: TheStreet, Biotech, Medicine, Healthcare Industry

Information Technology

European Commission Approves Bristol-Myers Squibb's Daklinza...

Bristol-Myers Squibb Company i 1 2 today announced that the European Commission has approved Daklinza , a potent, pan-genotypic NS5A replication complex inhibitor , for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Hepatitis, Health, Marketing, World News, Germany

TheStreet.com

Analysts' Actions: Akamai, Bristol-Myers, Eli Lilly, Merck, Pfizer

Twelve-month price target is $71. Company is an industry leader that can benefit from multiple secular trends, Robert Baird said.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly

TheStreet.com

Analysts' Actions: Akamai, Bristol-Myers, Eli Lilly, Merck, Pfizer

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Eli Lilly, Mozilla, TheStreet

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Corp., le principal fabricant de blocs d'alimentation portables et geant technologique a l'origine des marques Energizer , SpareOneTM et PowerSkin la... )--Research and Markets has announced the addition of the "ICT investment trends in Germany - Enterprise ICT... )--Regulatory News: Trelleborg Charlotta Grahs has been appointed as the new General ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Televisions

Mon Aug 25, 2014

Reuters

Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Oncology, Merck & Co., Food and Drug Administration, Skin Cancer, Health

Fri Aug 22, 2014

The Motley Fool

3 Reasons Bristol-Myers Squibb's Stock Could Rise

The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Amylin Pharmaceuticals

Thu Aug 21, 2014

Customer Interaction Solutions

U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein...

U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism , and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy Bristol-Myers Squibb Company and Pfizer Inc. today announced the U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Eliquis for the ... (more)

Comment?

Related Topix: Healthcare Law, Food and Drug Administration, Law, Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex, Pfizer

Reuters

FDA OKs use of Eliquis to treat leg, lung clots

Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat dangerous blood clots in the legs and lungs.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry

Wed Aug 20, 2014

Biopharm

Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen

Bristol-Myers Squibb and Celgene have established a clinical-trial collaboration to evaluate the safety, tolerability, and preliminary efficacy of a combination regimen of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, OPDIVO , and Celgene's nab technology-based chemotherapy ABRAXANE , in a Phase I study.

Comment?

Related Topix: Bloomsbury Publishing, Biotech, Bristol Myers Squibb, Publishing, Media, Medarex, Medicine, Bristol-Myers Squibb, Pharmaceuticals, Healthcare Industry, Cancer, Health

Business Wire

Press release distribution, EDGAR filing, XBRL, regulatory filings

Superfish is the #1 ranked software... )--CTRL was formed to create a forum where an open source philosophy is used to incorporate the best ideas in the practice of law through a range of technological innov... )--The AcroMetrix Oncology Hotspot Control provides a quality control material that can be used in laboratories with different NGS ... (more)

Comment?

Related Topix: Semiconductors, Vishay Intertechnology, Electronics, Biotech, Medicine, Healthcare Industry, Pfizer, Energy, AES, Retail, Target

Tue Aug 19, 2014

AmericanBankingNews.com

Bristol-Myers Squibb SVP Sells $997,800 in Stock

Bristol-Myers Squibb SVP Autenried Paul Von unloaded 20,000 shares of the company's stock on the open market in a transaction dated Tuesday, August 19th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Publishing, Media, Medarex

Mon Aug 18, 2014

Business Journal

Bristol-Myers Squibb targets major block of space in East Cambridge

Bristol-Myers Squibb is vetting several property options in East Cambridge, increasingly the office and lab market of choice for many of the largest life sciences companies in the world.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Bloomsbury Publishing, Bristol Myers Squibb, Publishing, Media, Medarex, Bristol-Myers Squibb, Pharmaceuticals, Waltham, MA

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••